Deerfield Management
PRVB

Deerfield Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Deerfield Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-725,000
Closed -$4.95M – 100
2019
Q3 		$4.95M Buy
+725,000
New +$7.33M 0.2% 72

Other funds holding PRVB

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Deerfield Management's PRVB Position: Q4 2019 in Review

Deerfield Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2019, closing a stake of 725,000 shares — an estimated $4.95M sold.

Deerfield Management first reported a position in PRVB in Q3 2019 and held it in 1 quarter. The position peaked at $4.95M in Q3 2019. 60 funds tracked by Wall St. Rank hold PRVB as of Q4 2019.

  • Deerfield Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Deerfield Management sold 725,000 Provention Bio, Inc. Common Stock shares in Q4 2019, an estimated $4.95M.
  • Deerfield Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Deerfield Management's Provention Bio, Inc. Common Stock position peaked at $4.95M in Q3 2019.
  • 60 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2019.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.